Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, ...
A webcast of the presentations will be available in the Investors and News section of the Ventyx website at A webcast replay will also be available on this website shortly after conclusion of each ...
Targeting the enzyme TYK2 could be a potential strategy to combat Alzheimer's disease. Researchers found that TYK2 plays a ...
Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital and collaborating institutions discovered that the enzyme ...
Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas ...
Scientists have discovered that the enzyme TYK2 modifies tau proteins, leading to their accumulation in the brain—a key ...
Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical ...
Biogen Inc. has identified non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, autoimmune disease, cardiovascular disorders, fibrosis, inflammatory ...
Alumis Inc. (ALMS) has received a new Buy rating, initiated by Robert W. Baird analyst, Brian Skorney. Brian Skorney has given his Buy rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback